Analysis of Solvency Ratios
Quarterly Data
Solvency ratios also known as long-term debt ratios measure a company ability to meet long-term obligations.
Solvency Ratios (Summary)
Vertex Pharmaceuticals Inc., solvency ratios (quarterly data)
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Vertex Pharmaceuticals Inc. debt to equity ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
| Debt to equity (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Vertex Pharmaceuticals Inc. debt to equity ratio (including operating lease liability) improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Vertex Pharmaceuticals Inc. debt to capital ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
| Debt to capital (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Vertex Pharmaceuticals Inc. debt to capital ratio (including operating lease liability) improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Vertex Pharmaceuticals Inc. debt to assets ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
| Debt to assets (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Vertex Pharmaceuticals Inc. debt to assets ratio (including operating lease liability) improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Vertex Pharmaceuticals Inc. financial leverage ratio increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023. |
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Vertex Pharmaceuticals Inc. interest coverage ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Debt to Equity
Vertex Pharmaceuticals Inc., debt to equity calculation (quarterly data)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Long-term finance lease liabilities | 376,100) | 390,300) | 404,100) | 417,600) | 430,800) | 442,300) | 482,300) | 495,500) | 509,800) | 513,255) | 524,925) | 530,330) | 539,042) | 546,514) | 522,067) | 532,952) | 538,576) | 541,561) | 551,530) | 560,381) | ||||||
| Total debt | 376,100) | 390,300) | 404,100) | 417,600) | 430,800) | 442,300) | 482,300) | 495,500) | 509,800) | 513,255) | 524,925) | 530,330) | 539,042) | 546,514) | 522,067) | 532,952) | 538,576) | 541,561) | 551,530) | 560,381) | ||||||
| Shareholders’ equity | 17,580,400) | 16,512,800) | 15,470,200) | 14,432,300) | 13,912,700) | 13,029,600) | 11,933,500) | 10,907,000) | 10,100,000) | 9,530,708) | 9,196,396) | 8,980,254) | 8,686,815) | 8,133,473) | 7,519,242) | 6,461,654) | 6,085,244) | 5,253,394) | 5,069,965) | 4,723,313) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to equity1 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | 0.09 | 0.10 | 0.11 | 0.12 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Equity, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | 5.73 | 5.02 | 4.74 | 4.68 | 3.67 | 4.35 | 4.98 | 4.51 | 4.98 | 5.96 | 6.53 | 6.24 | 6.58 | 5.70 | 5.94 | — | — | — | — | — | ||||||
| Amgen Inc. | 10.37 | 7.90 | 9.08 | 11.52 | 10.64 | 10.60 | 15.10 | 40.23 | 4.97 | 4.57 | 3.98 | 3.50 | 3.51 | 3.13 | 3.21 | 3.36 | 3.09 | 2.73 | 2.84 | 3.05 | ||||||
| Bristol-Myers Squibb Co. | 1.35 | 1.30 | 1.18 | 1.19 | 1.27 | 1.20 | 1.29 | 1.42 | 1.24 | 1.20 | 1.23 | 1.23 | 1.34 | 0.90 | 0.95 | 0.94 | 0.91 | 1.41 | 1.56 | 0.40 | ||||||
| Danaher Corp. | 0.34 | 0.42 | 0.38 | 0.39 | 0.39 | 0.41 | 0.43 | 0.47 | 0.49 | 0.54 | 0.48 | 0.50 | 0.53 | 0.57 | 0.62 | 0.84 | 0.72 | 0.54 | 0.32 | 0.30 | ||||||
| Eli Lilly & Co. | 2.34 | 1.80 | 1.70 | 1.69 | 1.52 | 1.58 | 1.97 | 1.77 | 1.88 | 2.20 | 2.56 | 2.35 | 2.94 | 3.51 | 3.99 | 5.60 | 5.88 | 4.50 | 5.68 | 6.44 | ||||||
| Gilead Sciences Inc. | 1.09 | 1.12 | 1.19 | 1.20 | 1.19 | 1.20 | 1.30 | 1.32 | 1.27 | 1.29 | 1.53 | 1.59 | 1.73 | 1.68 | 1.34 | 1.09 | 1.09 | 1.19 | 1.15 | 1.21 | ||||||
| Johnson & Johnson | 0.43 | 0.42 | 0.61 | 0.75 | 0.52 | 0.43 | 0.43 | 0.44 | 0.46 | 0.48 | 0.48 | 0.51 | 0.56 | 0.59 | 0.48 | 0.45 | 0.47 | 0.50 | 0.48 | 0.50 | ||||||
| Merck & Co. Inc. | 0.93 | 0.85 | 0.95 | 0.66 | 0.67 | 0.68 | 0.73 | 0.78 | 0.87 | 0.74 | 0.80 | 1.16 | 1.26 | 0.98 | 1.12 | 1.07 | 1.02 | 0.97 | 0.96 | 0.94 | ||||||
| Moderna Inc. | 0.04 | 0.04 | 0.05 | 0.04 | 0.05 | 0.05 | 0.04 | 0.04 | 0.04 | 0.02 | 0.05 | 0.04 | 0.04 | 0.04 | 0.02 | 0.02 | 0.03 | 0.04 | 0.03 | 0.03 | ||||||
| Pfizer Inc. | 0.81 | 0.66 | 0.66 | 0.36 | 0.37 | 0.40 | 0.46 | 0.44 | 0.50 | 0.53 | 0.56 | 0.58 | 0.63 | 0.97 | 0.99 | 0.80 | 0.83 | 0.81 | 0.78 | 0.77 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.10 | 0.11 | 0.11 | 0.11 | 0.12 | 0.13 | 0.13 | 0.14 | 0.14 | 0.16 | 0.18 | 0.23 | 0.24 | 0.27 | 0.24 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | ||||||
| Thermo Fisher Scientific Inc. | 0.75 | 0.78 | 0.78 | 0.83 | 0.78 | 0.67 | 0.72 | 0.81 | 0.85 | 0.56 | 0.51 | 0.53 | 0.63 | 0.66 | 0.71 | 0.70 | 0.60 | 0.58 | 0.66 | 0.66 | ||||||
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Debt to equity = Total debt ÷ Shareholders’ equity
= 376,100 ÷ 17,580,400 = 0.02
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity ratio | A solvency ratio calculated as total debt divided by total shareholders’ equity. | Vertex Pharmaceuticals Inc. debt to equity ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Debt to Equity (including Operating Lease Liability)
Vertex Pharmaceuticals Inc., debt to equity (including operating lease liability) calculation (quarterly data)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Long-term finance lease liabilities | 376,100) | 390,300) | 404,100) | 417,600) | 430,800) | 442,300) | 482,300) | 495,500) | 509,800) | 513,255) | 524,925) | 530,330) | 539,042) | 546,514) | 522,067) | 532,952) | 538,576) | 541,561) | 551,530) | 560,381) | ||||||
| Total debt | 376,100) | 390,300) | 404,100) | 417,600) | 430,800) | 442,300) | 482,300) | 495,500) | 509,800) | 513,255) | 524,925) | 530,330) | 539,042) | 546,514) | 522,067) | 532,952) | 538,576) | 541,561) | 551,530) | 560,381) | ||||||
| Long-term operating lease liabilities | 348,600) | 354,400) | 363,500) | 371,600) | 379,500) | 382,300) | 365,000) | 377,000) | 377,400) | 363,545) | 368,924) | 368,467) | 350,463) | —) | —) | —) | —) | —) | —) | —) | ||||||
| Total debt (including operating lease liability) | 724,700) | 744,700) | 767,600) | 789,200) | 810,300) | 824,600) | 847,300) | 872,500) | 887,200) | 876,800) | 893,849) | 898,797) | 889,505) | 546,514) | 522,067) | 532,952) | 538,576) | 541,561) | 551,530) | 560,381) | ||||||
| Shareholders’ equity | 17,580,400) | 16,512,800) | 15,470,200) | 14,432,300) | 13,912,700) | 13,029,600) | 11,933,500) | 10,907,000) | 10,100,000) | 9,530,708) | 9,196,396) | 8,980,254) | 8,686,815) | 8,133,473) | 7,519,242) | 6,461,654) | 6,085,244) | 5,253,394) | 5,069,965) | 4,723,313) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to equity (including operating lease liability)1 | 0.04 | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 | 0.07 | 0.08 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.07 | 0.07 | 0.08 | 0.09 | 0.10 | 0.11 | 0.12 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Equity (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||
| Moderna Inc. | 0.09 | 0.09 | 0.06 | 0.05 | 0.05 | 0.06 | 0.04 | 0.04 | 0.05 | 0.03 | 0.06 | 0.06 | 0.08 | 0.08 | 0.06 | 0.09 | 0.11 | 0.04 | 0.03 | 0.03 | ||||||
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Debt to equity (including operating lease liability) = Total debt (including operating lease liability) ÷ Shareholders’ equity
= 724,700 ÷ 17,580,400 = 0.04
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to equity (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total shareholders’ equity. | Vertex Pharmaceuticals Inc. debt to equity ratio (including operating lease liability) improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Debt to Capital
Vertex Pharmaceuticals Inc., debt to capital calculation (quarterly data)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Long-term finance lease liabilities | 376,100) | 390,300) | 404,100) | 417,600) | 430,800) | 442,300) | 482,300) | 495,500) | 509,800) | 513,255) | 524,925) | 530,330) | 539,042) | 546,514) | 522,067) | 532,952) | 538,576) | 541,561) | 551,530) | 560,381) | ||||||
| Total debt | 376,100) | 390,300) | 404,100) | 417,600) | 430,800) | 442,300) | 482,300) | 495,500) | 509,800) | 513,255) | 524,925) | 530,330) | 539,042) | 546,514) | 522,067) | 532,952) | 538,576) | 541,561) | 551,530) | 560,381) | ||||||
| Shareholders’ equity | 17,580,400) | 16,512,800) | 15,470,200) | 14,432,300) | 13,912,700) | 13,029,600) | 11,933,500) | 10,907,000) | 10,100,000) | 9,530,708) | 9,196,396) | 8,980,254) | 8,686,815) | 8,133,473) | 7,519,242) | 6,461,654) | 6,085,244) | 5,253,394) | 5,069,965) | 4,723,313) | ||||||
| Total capital | 17,956,500) | 16,903,100) | 15,874,300) | 14,849,900) | 14,343,500) | 13,471,900) | 12,415,800) | 11,402,500) | 10,609,800) | 10,043,963) | 9,721,321) | 9,510,584) | 9,225,857) | 8,679,987) | 8,041,309) | 6,994,606) | 6,623,820) | 5,794,955) | 5,621,495) | 5,283,694) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to capital1 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 | 0.06 | 0.06 | 0.08 | 0.08 | 0.09 | 0.10 | 0.11 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Capital, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | 0.85 | 0.83 | 0.83 | 0.82 | 0.79 | 0.81 | 0.83 | 0.82 | 0.83 | 0.86 | 0.87 | 0.86 | 0.87 | 0.85 | 0.86 | 1.12 | 1.14 | 1.27 | 1.30 | 1.27 | ||||||
| Amgen Inc. | 0.91 | 0.89 | 0.90 | 0.92 | 0.91 | 0.91 | 0.94 | 0.98 | 0.83 | 0.82 | 0.80 | 0.78 | 0.78 | 0.76 | 0.76 | 0.77 | 0.76 | 0.73 | 0.74 | 0.75 | ||||||
| Bristol-Myers Squibb Co. | 0.57 | 0.56 | 0.54 | 0.54 | 0.56 | 0.54 | 0.56 | 0.59 | 0.55 | 0.55 | 0.55 | 0.55 | 0.57 | 0.47 | 0.49 | 0.48 | 0.48 | 0.59 | 0.61 | 0.28 | ||||||
| Danaher Corp. | 0.26 | 0.30 | 0.28 | 0.28 | 0.28 | 0.29 | 0.30 | 0.32 | 0.33 | 0.35 | 0.32 | 0.33 | 0.35 | 0.37 | 0.38 | 0.46 | 0.42 | 0.35 | 0.24 | 0.23 | ||||||
| Eli Lilly & Co. | 0.70 | 0.64 | 0.63 | 0.63 | 0.60 | 0.61 | 0.66 | 0.64 | 0.65 | 0.69 | 0.72 | 0.70 | 0.75 | 0.78 | 0.80 | 0.85 | 0.85 | 0.82 | 0.85 | 0.87 | ||||||
| Gilead Sciences Inc. | 0.52 | 0.53 | 0.54 | 0.55 | 0.54 | 0.54 | 0.56 | 0.57 | 0.56 | 0.56 | 0.60 | 0.61 | 0.63 | 0.63 | 0.57 | 0.52 | 0.52 | 0.54 | 0.54 | 0.55 | ||||||
| Johnson & Johnson | 0.30 | 0.30 | 0.38 | 0.43 | 0.34 | 0.30 | 0.30 | 0.31 | 0.31 | 0.33 | 0.32 | 0.34 | 0.36 | 0.37 | 0.33 | 0.31 | 0.32 | 0.33 | 0.33 | 0.33 | ||||||
| Merck & Co. Inc. | 0.48 | 0.46 | 0.49 | 0.40 | 0.40 | 0.41 | 0.42 | 0.44 | 0.46 | 0.42 | 0.44 | 0.54 | 0.56 | 0.50 | 0.53 | 0.52 | 0.50 | 0.49 | 0.49 | 0.48 | ||||||
| Moderna Inc. | 0.04 | 0.04 | 0.05 | 0.04 | 0.05 | 0.05 | 0.03 | 0.04 | 0.04 | 0.02 | 0.05 | 0.03 | 0.04 | 0.04 | 0.02 | 0.02 | 0.03 | 0.04 | 0.03 | 0.03 | ||||||
| Pfizer Inc. | 0.45 | 0.40 | 0.40 | 0.26 | 0.27 | 0.28 | 0.32 | 0.31 | 0.33 | 0.35 | 0.36 | 0.37 | 0.39 | 0.49 | 0.50 | 0.45 | 0.45 | 0.45 | 0.44 | 0.43 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.12 | 0.12 | 0.13 | 0.14 | 0.15 | 0.18 | 0.20 | 0.21 | 0.20 | 0.06 | 0.06 | 0.06 | 0.07 | 0.07 | ||||||
| Thermo Fisher Scientific Inc. | 0.43 | 0.44 | 0.44 | 0.45 | 0.44 | 0.40 | 0.42 | 0.45 | 0.46 | 0.36 | 0.34 | 0.35 | 0.39 | 0.40 | 0.42 | 0.41 | 0.37 | 0.37 | 0.40 | 0.40 | ||||||
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Debt to capital = Total debt ÷ Total capital
= 376,100 ÷ 17,956,500 = 0.02
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital ratio | A solvency ratio calculated as total debt divided by total debt plus shareholders’ equity. | Vertex Pharmaceuticals Inc. debt to capital ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Debt to Capital (including Operating Lease Liability)
Vertex Pharmaceuticals Inc., debt to capital (including operating lease liability) calculation (quarterly data)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Long-term finance lease liabilities | 376,100) | 390,300) | 404,100) | 417,600) | 430,800) | 442,300) | 482,300) | 495,500) | 509,800) | 513,255) | 524,925) | 530,330) | 539,042) | 546,514) | 522,067) | 532,952) | 538,576) | 541,561) | 551,530) | 560,381) | ||||||
| Total debt | 376,100) | 390,300) | 404,100) | 417,600) | 430,800) | 442,300) | 482,300) | 495,500) | 509,800) | 513,255) | 524,925) | 530,330) | 539,042) | 546,514) | 522,067) | 532,952) | 538,576) | 541,561) | 551,530) | 560,381) | ||||||
| Long-term operating lease liabilities | 348,600) | 354,400) | 363,500) | 371,600) | 379,500) | 382,300) | 365,000) | 377,000) | 377,400) | 363,545) | 368,924) | 368,467) | 350,463) | —) | —) | —) | —) | —) | —) | —) | ||||||
| Total debt (including operating lease liability) | 724,700) | 744,700) | 767,600) | 789,200) | 810,300) | 824,600) | 847,300) | 872,500) | 887,200) | 876,800) | 893,849) | 898,797) | 889,505) | 546,514) | 522,067) | 532,952) | 538,576) | 541,561) | 551,530) | 560,381) | ||||||
| Shareholders’ equity | 17,580,400) | 16,512,800) | 15,470,200) | 14,432,300) | 13,912,700) | 13,029,600) | 11,933,500) | 10,907,000) | 10,100,000) | 9,530,708) | 9,196,396) | 8,980,254) | 8,686,815) | 8,133,473) | 7,519,242) | 6,461,654) | 6,085,244) | 5,253,394) | 5,069,965) | 4,723,313) | ||||||
| Total capital (including operating lease liability) | 18,305,100) | 17,257,500) | 16,237,800) | 15,221,500) | 14,723,000) | 13,854,200) | 12,780,800) | 11,779,500) | 10,987,200) | 10,407,508) | 10,090,245) | 9,879,051) | 9,576,320) | 8,679,987) | 8,041,309) | 6,994,606) | 6,623,820) | 5,794,955) | 5,621,495) | 5,283,694) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to capital (including operating lease liability)1 | 0.04 | 0.04 | 0.05 | 0.05 | 0.06 | 0.06 | 0.07 | 0.07 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.06 | 0.06 | 0.08 | 0.08 | 0.09 | 0.10 | 0.11 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Capital (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||
| Moderna Inc. | 0.08 | 0.09 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.05 | 0.03 | 0.06 | 0.06 | 0.07 | 0.07 | 0.05 | 0.08 | 0.10 | 0.04 | 0.03 | 0.03 | ||||||
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Debt to capital (including operating lease liability) = Total debt (including operating lease liability) ÷ Total capital (including operating lease liability)
= 724,700 ÷ 18,305,100 = 0.04
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to capital (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total debt (including operating lease liability) plus shareholders’ equity. | Vertex Pharmaceuticals Inc. debt to capital ratio (including operating lease liability) improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Debt to Assets
Vertex Pharmaceuticals Inc., debt to assets calculation (quarterly data)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Long-term finance lease liabilities | 376,100) | 390,300) | 404,100) | 417,600) | 430,800) | 442,300) | 482,300) | 495,500) | 509,800) | 513,255) | 524,925) | 530,330) | 539,042) | 546,514) | 522,067) | 532,952) | 538,576) | 541,561) | 551,530) | 560,381) | ||||||
| Total debt | 376,100) | 390,300) | 404,100) | 417,600) | 430,800) | 442,300) | 482,300) | 495,500) | 509,800) | 513,255) | 524,925) | 530,330) | 539,042) | 546,514) | 522,067) | 532,952) | 538,576) | 541,561) | 551,530) | 560,381) | ||||||
| Total assets | 22,730,200) | 21,726,200) | 20,349,200) | 18,974,200) | 18,150,900) | 16,706,400) | 15,582,200) | 14,256,100) | 13,432,500) | 12,618,745) | 12,221,686) | 12,115,059) | 11,751,808) | 11,301,633) | 10,216,367) | 8,893,201) | 8,318,465) | 7,514,553) | 7,033,471) | 6,543,114) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to assets1 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 | 0.06 | 0.06 | 0.07 | 0.08 | 0.09 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Assets, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | 0.44 | 0.45 | 0.45 | 0.46 | 0.46 | 0.49 | 0.51 | 0.51 | 0.52 | 0.54 | 0.56 | 0.57 | 0.57 | 0.58 | 0.58 | 0.74 | 0.75 | 0.65 | 0.65 | 0.65 | ||||||
| Amgen Inc. | 0.67 | 0.67 | 0.68 | 0.69 | 0.60 | 0.61 | 0.62 | 0.62 | 0.54 | 0.58 | 0.55 | 0.52 | 0.52 | 0.53 | 0.53 | 0.52 | 0.50 | 0.50 | 0.52 | 0.52 | ||||||
| Bristol-Myers Squibb Co. | 0.42 | 0.41 | 0.40 | 0.40 | 0.41 | 0.40 | 0.42 | 0.44 | 0.41 | 0.40 | 0.41 | 0.41 | 0.43 | 0.36 | 0.36 | 0.36 | 0.36 | 0.43 | 0.45 | 0.17 | ||||||
| Danaher Corp. | 0.22 | 0.25 | 0.23 | 0.23 | 0.23 | 0.24 | 0.25 | 0.26 | 0.27 | 0.29 | 0.26 | 0.27 | 0.28 | 0.30 | 0.31 | 0.38 | 0.35 | 0.29 | 0.19 | 0.18 | ||||||
| Eli Lilly & Co. | 0.39 | 0.35 | 0.34 | 0.36 | 0.33 | 0.33 | 0.36 | 0.35 | 0.35 | 0.35 | 0.35 | 0.35 | 0.36 | 0.39 | 0.39 | 0.42 | 0.39 | 0.40 | 0.41 | 0.42 | ||||||
| Gilead Sciences Inc. | 0.40 | 0.40 | 0.40 | 0.41 | 0.40 | 0.40 | 0.42 | 0.42 | 0.39 | 0.41 | 0.44 | 0.45 | 0.46 | 0.48 | 0.43 | 0.40 | 0.40 | 0.42 | 0.41 | 0.42 | ||||||
| Johnson & Johnson | 0.18 | 0.18 | 0.24 | 0.27 | 0.21 | 0.18 | 0.18 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.20 | 0.22 | 0.19 | 0.18 | 0.18 | 0.19 | 0.19 | 0.20 | ||||||
| Merck & Co. Inc. | 0.33 | 0.33 | 0.35 | 0.29 | 0.28 | 0.28 | 0.30 | 0.30 | 0.31 | 0.28 | 0.29 | 0.34 | 0.35 | 0.32 | 0.34 | 0.33 | 0.31 | 0.31 | 0.32 | 0.31 | ||||||
| Moderna Inc. | 0.03 | 0.03 | 0.04 | 0.03 | 0.04 | 0.04 | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | ||||||
| Pfizer Inc. | 0.32 | 0.30 | 0.30 | 0.18 | 0.18 | 0.19 | 0.21 | 0.20 | 0.21 | 0.22 | 0.23 | 0.25 | 0.26 | 0.35 | 0.36 | 0.31 | 0.31 | 0.31 | 0.30 | 0.29 | ||||||
| Regeneron Pharmaceuticals Inc. | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.11 | 0.11 | 0.13 | 0.15 | 0.16 | 0.17 | 0.15 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | ||||||
| Thermo Fisher Scientific Inc. | 0.35 | 0.36 | 0.36 | 0.37 | 0.35 | 0.32 | 0.33 | 0.36 | 0.37 | 0.29 | 0.28 | 0.28 | 0.31 | 0.33 | 0.35 | 0.34 | 0.30 | 0.30 | 0.33 | 0.33 | ||||||
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Debt to assets = Total debt ÷ Total assets
= 376,100 ÷ 22,730,200 = 0.02
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets ratio | A solvency ratio calculated as total debt divided by total assets. | Vertex Pharmaceuticals Inc. debt to assets ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Debt to Assets (including Operating Lease Liability)
Vertex Pharmaceuticals Inc., debt to assets (including operating lease liability) calculation (quarterly data)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Long-term finance lease liabilities | 376,100) | 390,300) | 404,100) | 417,600) | 430,800) | 442,300) | 482,300) | 495,500) | 509,800) | 513,255) | 524,925) | 530,330) | 539,042) | 546,514) | 522,067) | 532,952) | 538,576) | 541,561) | 551,530) | 560,381) | ||||||
| Total debt | 376,100) | 390,300) | 404,100) | 417,600) | 430,800) | 442,300) | 482,300) | 495,500) | 509,800) | 513,255) | 524,925) | 530,330) | 539,042) | 546,514) | 522,067) | 532,952) | 538,576) | 541,561) | 551,530) | 560,381) | ||||||
| Long-term operating lease liabilities | 348,600) | 354,400) | 363,500) | 371,600) | 379,500) | 382,300) | 365,000) | 377,000) | 377,400) | 363,545) | 368,924) | 368,467) | 350,463) | —) | —) | —) | —) | —) | —) | —) | ||||||
| Total debt (including operating lease liability) | 724,700) | 744,700) | 767,600) | 789,200) | 810,300) | 824,600) | 847,300) | 872,500) | 887,200) | 876,800) | 893,849) | 898,797) | 889,505) | 546,514) | 522,067) | 532,952) | 538,576) | 541,561) | 551,530) | 560,381) | ||||||
| Total assets | 22,730,200) | 21,726,200) | 20,349,200) | 18,974,200) | 18,150,900) | 16,706,400) | 15,582,200) | 14,256,100) | 13,432,500) | 12,618,745) | 12,221,686) | 12,115,059) | 11,751,808) | 11,301,633) | 10,216,367) | 8,893,201) | 8,318,465) | 7,514,553) | 7,033,471) | 6,543,114) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Debt to assets (including operating lease liability)1 | 0.03 | 0.03 | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | 0.06 | 0.07 | 0.07 | 0.07 | 0.07 | 0.08 | 0.05 | 0.05 | 0.06 | 0.06 | 0.07 | 0.08 | 0.09 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Debt to Assets (including Operating Lease Liability), Competitors2 | ||||||||||||||||||||||||||
| Moderna Inc. | 0.07 | 0.07 | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 | 0.02 | 0.03 | 0.04 | 0.05 | 0.07 | 0.08 | 0.03 | 0.03 | 0.02 | ||||||
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Debt to assets (including operating lease liability) = Total debt (including operating lease liability) ÷ Total assets
= 724,700 ÷ 22,730,200 = 0.03
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Debt to assets (including operating lease liability) ratio | A solvency ratio calculated as total debt (including operating lease liability) divided by total assets. | Vertex Pharmaceuticals Inc. debt to assets ratio (including operating lease liability) improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Financial Leverage
Vertex Pharmaceuticals Inc., financial leverage calculation (quarterly data)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Total assets | 22,730,200) | 21,726,200) | 20,349,200) | 18,974,200) | 18,150,900) | 16,706,400) | 15,582,200) | 14,256,100) | 13,432,500) | 12,618,745) | 12,221,686) | 12,115,059) | 11,751,808) | 11,301,633) | 10,216,367) | 8,893,201) | 8,318,465) | 7,514,553) | 7,033,471) | 6,543,114) | ||||||
| Shareholders’ equity | 17,580,400) | 16,512,800) | 15,470,200) | 14,432,300) | 13,912,700) | 13,029,600) | 11,933,500) | 10,907,000) | 10,100,000) | 9,530,708) | 9,196,396) | 8,980,254) | 8,686,815) | 8,133,473) | 7,519,242) | 6,461,654) | 6,085,244) | 5,253,394) | 5,069,965) | 4,723,313) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Financial leverage1 | 1.29 | 1.32 | 1.32 | 1.31 | 1.30 | 1.28 | 1.31 | 1.31 | 1.33 | 1.32 | 1.33 | 1.35 | 1.35 | 1.39 | 1.36 | 1.38 | 1.37 | 1.43 | 1.39 | 1.39 | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Financial Leverage, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | 13.00 | 11.26 | 10.52 | 10.14 | 8.04 | 8.84 | 9.77 | 8.80 | 9.51 | 10.99 | 11.77 | 10.98 | 11.51 | 9.80 | 10.17 | — | — | — | — | — | ||||||
| Amgen Inc. | 15.59 | 11.83 | 13.31 | 16.59 | 17.79 | 17.44 | 24.51 | 64.62 | 9.13 | 7.91 | 7.25 | 6.70 | 6.69 | 5.90 | 6.10 | 6.50 | 6.17 | 5.45 | 5.50 | 5.91 | ||||||
| Bristol-Myers Squibb Co. | 3.23 | 3.15 | 2.92 | 2.96 | 3.12 | 3.01 | 3.08 | 3.26 | 3.04 | 2.98 | 3.01 | 2.99 | 3.13 | 2.50 | 2.61 | 2.59 | 2.52 | 3.25 | 3.44 | 2.29 | ||||||
| Danaher Corp. | 1.58 | 1.67 | 1.64 | 1.65 | 1.68 | 1.72 | 1.76 | 1.80 | 1.84 | 1.90 | 1.82 | 1.87 | 1.92 | 1.92 | 1.97 | 2.22 | 2.05 | 1.89 | 1.66 | 1.64 | ||||||
| Eli Lilly & Co. | 5.94 | 5.16 | 4.95 | 4.75 | 4.65 | 4.71 | 5.51 | 5.03 | 5.44 | 6.21 | 7.42 | 6.79 | 8.27 | 9.10 | 10.25 | 13.35 | 15.07 | 11.20 | 13.91 | 15.32 | ||||||
| Gilead Sciences Inc. | 2.72 | 2.80 | 2.95 | 2.95 | 2.97 | 2.97 | 3.11 | 3.17 | 3.23 | 3.13 | 3.45 | 3.56 | 3.76 | 3.49 | 3.10 | 2.71 | 2.74 | 2.87 | 2.79 | 2.86 | ||||||
| Johnson & Johnson | 2.44 | 2.33 | 2.55 | 2.77 | 2.44 | 2.35 | 2.33 | 2.39 | 2.46 | 2.55 | 2.54 | 2.62 | 2.76 | 2.65 | 2.51 | 2.53 | 2.65 | 2.67 | 2.55 | 2.54 | ||||||
| Merck & Co. Inc. | 2.84 | 2.59 | 2.70 | 2.30 | 2.37 | 2.41 | 2.48 | 2.61 | 2.77 | 2.61 | 2.72 | 3.37 | 3.62 | 3.08 | 3.28 | 3.24 | 3.26 | 3.10 | 3.04 | 2.99 | ||||||
| Moderna Inc. | 1.33 | 1.45 | 1.29 | 1.28 | 1.35 | 1.45 | 1.45 | 1.62 | 1.74 | 2.07 | 2.41 | 3.31 | 2.86 | 1.69 | 1.18 | 1.26 | 1.35 | 1.27 | 1.26 | 1.25 | ||||||
| Pfizer Inc. | 2.54 | 2.22 | 2.22 | 1.94 | 2.06 | 2.10 | 2.24 | 2.23 | 2.35 | 2.37 | 2.43 | 2.31 | 2.44 | 2.74 | 2.77 | 2.56 | 2.65 | 2.62 | 2.62 | 2.64 | ||||||
| Regeneron Pharmaceuticals Inc. | 1.27 | 1.29 | 1.28 | 1.28 | 1.29 | 1.29 | 1.32 | 1.32 | 1.36 | 1.37 | 1.42 | 1.48 | 1.56 | 1.59 | 1.59 | 1.30 | 1.34 | 1.33 | 1.35 | 1.36 | ||||||
| Thermo Fisher Scientific Inc. | 2.11 | 2.14 | 2.15 | 2.24 | 2.21 | 2.08 | 2.14 | 2.26 | 2.33 | 1.90 | 1.84 | 1.88 | 2.00 | 2.01 | 2.06 | 2.05 | 1.97 | 1.93 | 2.02 | 2.01 | ||||||
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Financial leverage = Total assets ÷ Shareholders’ equity
= 22,730,200 ÷ 17,580,400 = 1.29
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Financial leverage ratio | A solvency ratio calculated as total assets divided by total shareholders’ equity. | Vertex Pharmaceuticals Inc. financial leverage ratio increased from Q2 2023 to Q3 2023 but then decreased significantly from Q3 2023 to Q4 2023. |
Interest Coverage
Vertex Pharmaceuticals Inc., interest coverage calculation (quarterly data)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Net income | 968,800) | 1,035,300) | 915,700) | 699,800) | 818,900) | 930,500) | 810,500) | 762,100) | 770,110) | 851,928) | 66,924) | 653,138) | 604,190) | 667,434) | 837,270) | 602,753) | 583,234) | 57,518) | 267,427) | 268,631) | ||||||
| Add: Income tax expense | 178,800) | 143,900) | 245,800) | 191,700) | 257,900) | 245,900) | 213,900) | 192,700) | 100,844) | 230,813) | (111,179) | 167,822) | 284,433) | 78,437) | (12,500) | 54,781) | 93,716) | 13,148) | 59,711) | 51,534) | ||||||
| Add: Interest expense | 10,600) | 10,900) | 11,200) | 11,400) | 11,600) | 13,700) | 14,600) | 14,900) | 15,089) | 15,255) | 15,478) | 15,678) | 16,288) | 13,856) | 13,871) | 14,136) | 14,249) | 14,548) | 14,837) | 14,868) | ||||||
| Earnings before interest and tax (EBIT) | 1,158,200) | 1,190,100) | 1,172,700) | 902,900) | 1,088,400) | 1,190,100) | 1,039,000) | 969,700) | 886,043) | 1,097,996) | (28,777) | 836,638) | 904,911) | 759,727) | 838,641) | 671,670) | 691,199) | 85,214) | 341,975) | 335,033) | ||||||
| Solvency Ratio | ||||||||||||||||||||||||||
| Interest coverage1 | 100.32 | 96.54 | 90.90 | 82.27 | 78.23 | 70.08 | 66.72 | 48.17 | 45.40 | 44.83 | 40.33 | 55.95 | 54.60 | 52.77 | 40.26 | 30.99 | 24.84 | — | — | — | ||||||
| Benchmarks | ||||||||||||||||||||||||||
| Interest Coverage, Competitors2 | ||||||||||||||||||||||||||
| Amgen Inc. | 3.73 | 4.54 | 5.43 | 6.51 | 6.22 | 6.83 | 6.97 | 6.40 | 6.60 | 6.46 | 6.48 | 7.64 | 7.44 | 7.62 | 7.62 | 7.85 | 8.09 | — | — | — | ||||||
| Danaher Corp. | 18.64 | 23.66 | 29.65 | 35.60 | 40.30 | 41.32 | 35.26 | 33.54 | 32.92 | 28.74 | 25.87 | 21.54 | 17.35 | 16.90 | 20.00 | 25.33 | 31.44 | — | — | — | ||||||
| Gilead Sciences Inc. | 8.27 | 8.88 | 9.03 | 8.84 | 7.22 | 5.80 | 6.73 | 6.97 | 9.27 | 10.06 | 7.61 | 2.93 | 2.70 | 2.83 | 0.41 | 5.90 | 6.19 | — | — | — | ||||||
| Johnson & Johnson | 20.51 | 19.09 | 23.89 | 31.49 | 79.71 | 141.63 | 160.27 | 164.15 | 125.46 | 94.27 | 87.06 | 73.87 | 83.07 | 96.82 | 81.36 | 81.56 | 55.49 | — | — | — | ||||||
| Regeneron Pharmaceuticals Inc. | 58.52 | 61.70 | 69.61 | 73.97 | 82.80 | 108.62 | 116.35 | 163.24 | 163.75 | 139.74 | 104.12 | 68.20 | 67.97 | 72.22 | 108.12 | 90.22 | 81.43 | — | — | — | ||||||
| Thermo Fisher Scientific Inc. | 5.54 | 5.98 | 6.64 | 8.28 | 11.56 | 13.59 | 15.70 | 16.73 | 17.49 | 19.94 | 19.52 | 17.58 | 14.07 | 10.78 | 7.93 | 7.66 | 7.02 | — | — | — | ||||||
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q4 2023 Calculation
Interest coverage
= (EBITQ4 2023
+ EBITQ3 2023
+ EBITQ2 2023
+ EBITQ1 2023)
÷ (Interest expenseQ4 2023
+ Interest expenseQ3 2023
+ Interest expenseQ2 2023
+ Interest expenseQ1 2023)
= (1,158,200 + 1,190,100 + 1,172,700 + 902,900)
÷ (10,600 + 10,900 + 11,200 + 11,400)
= 100.32
2 Click competitor name to see calculations.
| Solvency ratio | Description | The company |
|---|---|---|
| Interest coverage ratio | A solvency ratio calculated as EBIT divided by interest payments. | Vertex Pharmaceuticals Inc. interest coverage ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |